Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation

The frequency of poor outcomes in relapsed leukemia patients underscores the need for novel therapeutic approaches. The FDA-approved immunosuppressant FTY720 limits leukemia progression by activating protein phosphatase 2A and restricting nutrient access. Unfortunately, FTY720 cannot be re-purposed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Main Authors: McCracken, Alison N., McMonigle, Ryan J., Tessier, Jérémie, Fransson, Rebecca, Perryman, Michael S., Chen, Bin, Keebaugh, Andrew, Selwan, Elizabeth, Barr, Sarah A., Kim, Seong M., Roy, Saurabh G., Liu, Gang, Fallegger, Daniel, Sernissi, Lorenzo, Brandt, Cordelia, Moitessier, Nicolas, Snider, Ashley J., Clare, Simon, Müschen, Markus, Huwiler, Andrea, Kleinman, Michael T., Hanessian, Stephen, Edinger, Aimee L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5332311/
https://ncbi.nlm.nih.gov/pubmed/27573555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2016.244
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados